0
0
April 16, 2026
HYDERABAD — A high-profile resignation by a prominent Hyderabad-based paediatrician has reignited a fierce national debate over the commercial labeling of Oral Rehydration Salts (ORS) in India. Dr. Sivaranjani Santosh recently stepped down from the Indian Academy of Paediatrics (IAP), alleging a lack of institutional support after she faced legal threats from pharmaceutical giants for criticizing products that use the “ORS” name without meeting medical standards. The controversy, unfolding this April, highlights a dangerous gap between corporate branding and life-saving medical science, leaving parents caught in the middle of a labeling war.
A Stand for Science Leads to Legal Firefights
The dispute centers on a fundamental medical distinction: the difference between a “thirst-quencher” and a “therapeutic drug.” Dr. Santosh has spent years advocating for stricter regulations on beverages marketed as ORS. She argues that many commercially available drinks use the “ORS” acronym despite containing sugar and salt levels that deviate significantly from the World Health Organization (WHO) and UNICEF-recommended formulas.
In response to her public advocacy, pharmaceutical companies, including Kenvue and Johnson & Johnson, reportedly issued legal notices to Dr. Santosh. These notices accused her of making defamatory statements and demanded the removal of social media content that educated parents on how to distinguish clinical ORS from sugary alternatives.
“I felt the IAP did not sufficiently back a member who was standing up for a public health cause,” Dr. Santosh stated regarding her resignation. Her departure has sent shockwaves through the Indian medical community, raising urgent questions about whether doctors can fulfill their duty to protect public health without facing personal legal peril.
The Science of Rehydration: Not All Drinks Are Equal
To the average consumer, a bottle labeled “ORS” appears to be a safe bet for a dehydrated child. However, in the world of paediatrics, ORS is a precision tool.
Since 2004, the WHO and UNICEF have recommended a “reduced-osmolarity” formula. This specific balance of glucose and electrolytes is designed to trigger a co-transport mechanism in the small intestine, allowing the body to absorb water rapidly during bouts of diarrhoea.
The WHO-Standard ORS Formula vs. Commercial Alternatives
| Component | WHO Standard (Reduced Osmolarity) | Typical “ORS-Style” Fruit Drinks |
| Glucose | 75 mmol/L | Often much higher (Sugar-heavy) |
| Sodium | 75 mmol/L | Often lower than therapeutic levels |
| Total Osmolarity | 245 mOsm/L | Varies; can be dangerously high |
| Purpose | Clinical treatment of dehydration | General hydration/Refreshing taste |
The medical stakes are incredibly high. According to the WHO, diarrhoeal disease is the third leading cause of death globally for children under five, claiming over 443,000 lives annually. In India, where sanitation challenges persist, the accessibility of accurate ORS is a primary pillar of child survival.
“ORS is not a casual health drink; it is a pharmaceutical-quality product,” says Dr. Aruna Sen (pseudonym), a public health researcher not involved in the dispute. “If a child with severe diarrhoea is given a drink with too much sugar—common in many commercial ‘ORS’ beverages—it can actually worsen the diarrhoea through osmotic effects, leading to dangerous levels of dehydration.”
Regulatory Friction and the “Chill Effect”
The Indian government has attempted to intervene. In October 2025, the Food Safety and Standards Authority of India (FSSAI) issued a directive restricting the use of the term “ORS” in product names unless they adhere to specific medical standards. Despite this, enforcement remains a challenge, and branding that “mimics” clinical ORS continues to flood pharmacy shelves.
The legal pressure on Dr. Santosh has sparked fears of a “chilling effect” on medical advocacy. If individual physicians fear lawsuits for pointing out discrepancies between a product’s label and its actual contents, the first line of defense for consumer safety is weakened.
“The issue here is the ‘look-alike, sound-alike’ problem,” explains a legal expert specializing in Indian health law. “When a commercial drink borrows the credibility of a medical term like ORS, it creates a dangerous confusion in the mind of a panicked parent at 2:00 AM.”
What This Means for Parents and Caregivers
While the legal battle continues in Hyderabad, the practical implications for families are immediate. Health experts urge parents to look beyond the large “ORS” lettering on the front of a bottle and check for the following:
-
WHO/UNICEF Compliance: Look for a label that explicitly states the product follows the WHO reduced-osmolarity formula.
-
The “Drug” vs. “Food” Label: In India, clinical ORS is usually licensed under the Drug Controller General of India (DCGI), whereas many commercial drinks are registered under FSSAI as “food” or “beverages.”
-
Consultation: Always use ORS as a treatment for illness, not as a routine beverage for healthy children.
Moving Forward: The Need for Institutional Support
The resignation of Dr. Santosh serves as a wake-up call for medical associations like the IAP. While the organization has previously supported ORS awareness, critics argue that medical bodies must do more to shield their members from corporate litigation when those members are communicating evidenced-based truths.
The resolution of this conflict will likely set a precedent for how medical products are marketed in India and how much freedom doctors have to challenge the status quo. For now, the message to the public is clear: labels can be misleading, and in the case of a sick child, the difference between a “drink” and a “medicine” can be life-saving.
References
-
News Reports: Reporting on Dr. Sivaranjani Santosh’s resignation, The News Minute and Telangana Today, April 2026.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
